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ABSTRACT
Endra Yustin E. S., Fajar Waskito, Yohanes Widodo Wirohadidjojo - The effect of combination of triamcinolone
acetonide and methotrexate on the keloid-fibroblast activity in dermis equivalent
Background: Triamcinolone acetonid (TA) intralesion has been a standard treatment for keloids for many
years, due to its effect in inhibiting collagen synthesis and fibroblast proliferation. However, until now the
clinical result is unsatisfactory. Keloid flattening is slow and sometimes adverse reactions may occur.
Methotrexate (MTX) is a chemotherapeutic agent having an antiproliferating effect which act as an antifolic
acid. Because of this effect, MTX is potential to be used in combination with TA for the treatment in
keloid. Fibroblast populated collagen lattice (FPCL) was a dermal equivalent usually used for fibroblast
activity measurement.
Objective: To understand the inhibition of fibroblast keloid activities of MTX in vitro on FPCL contraction,
compared to TA and MTX plus TA.
Methods: This research used simple parallel multigroups experimental study design, and conducted on third
passage keloid fibroblast culture, which was isolated from one patient. Fibroblast was cultivated in collagen
type 1 from rat tail (FPCL). Keloid fibroblasts was classified into 16 groups, and treated with 5, 10, 20
mM TA, 1.75, 3.5, 7 mM MTX, combination of TA and MTX, and a control negative. FPCL contraction
indicating activities of fibroblast was measured using Scion Image software. Mean of FPCL contraction
was analyzed using one way analysis of variance (ANOVA).
Results: All treatments could inhibit FPCL contraction until day 2 (p<0.05). The highest inhibition of FPCL
was found in combination of TA 20 mM + MTX 7 mM (p<0.05). The treatment that could inhibit FPCL
contraction until day 3 was only group MTX 3.5 mM + TA 20 mM. This result indicated that a combination
of TA and MTX was stronger in  inhibiting keloid fibroblast activities compared with TA and MTX alone.
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ABSTRAK
Endra Yustin E. S., Fajar Waskito, Yohanes Widodo Wirohadidjojo - Efek kombinasi triamsinolon asetonid
dan metotreksat terhadap aktivitas fibroblas keloid pada ekivalen jangat
Latar Belakang. Injeksi triamsinolon asetonid (TA) intralesi telah merupakan standar terapi keloid selama
beberapa tahun, karena dapat menghambat sintesis kolagen dan proliferasi fibroblas. Namun demikian,
sampai dewasa ini hasil klinisnya tidak memuaskan. Penipisan keloid terjadi sangat lamban dan kadang-
kadang timbul reaksi yang tidak diinginkan. Metotreksat (MTX) digunakan sebagai agen kemoterapi yang
memiliki efek antiproliferasi yang bekerja sebagai anti-asam folat. Oleh karena efek tersebut, MTX berpotensi
sebagai kombinasi dengan TA pada terapi keloid. Fibroblast populated collagen lattice  (FPCL) yang dikenal
sebagai ekivalen kulit jangat sering dipakai untuk menilai aktivitas fibroblas.
Tujuan: Mengetahui daya hambat aktivitas fibroblas keloid secara in vitro terhadap kontraksi FPCL antara
kombinasi TA dan MTX dalam berbagai dosis dengan berbagai dosis TA dan MTX secara tunggal.
Endra Yustin E. S, Departement of Dermatovenereology, Faculty of Medicine,
Gadjah Mada University/DR. Sardjito Hospital Yogyakarta
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Metode: Penelitian ini menggunakan rancangan penelitian eksperimental sederhana paralel multigrup, yang
memakai kultur fibroblas keloid  passage 3 dari satu penderita keloid. Fibroblas dibiakkan dalam kolagen
tipe 1 dari buntut tikus (FPCL). Fibroblas keloid dibagi menjadi 16 grup dan diterapi dengan TA 5, 10, 20
mM, MTX 1,75, 3,5, 7 mM, kombinasi TA dan MTX, dan kontrol negatif tanpa perlakuan. Kontraksi FPCL
sebagai indikasi aktivitas fibroblas keloid dinilai dengan  Scion Image software. Rerata luas FPCL diuji
dengan memakai analisis varian satu jalan (ANOVA).
Hasil: Kelompok MTX dan TA tunggal ataupun kombinasi pada semua dosis dapat menghambat FPCL pada
hari pertama dan kedua (p<0,05), hambatan terbesar dijumpai pada kombinasi MTX 7 mM + TA 20 mM
(p<0,05). Terapi yang dapat menghambat kontraksi  sampai hari ke-3 hanya dijumpai pada kelompok
MTX 3.5 mM + TA 20 mM. Hasil penelitian ini menunjukkan bahwa kombinasi TA + MTX lebih kuat
menghambat
aktivitas fibroblas keloid dibanding TA and MTX yang diberikan tersendiri.
INTRODUCTION
Keloids are benign hyperproliferative growth
of dermal collagen that is usually resulted from
excessive tissue response to skin trauma,1 expands
beyond the boundaries of the original injury as it
heals and does not regress spontaneously.2,3 Keloids
are often pruritic, painful, causes cosmetic
disfigurement and skin contracture.4 Keloids may
be caused by minor skin wound such as acne,
piercing, vaccination, or even a mosquito bite or
post-surgery, especially on presternal region,
superior back of the trunk and posterior region of
the neck.5 Keloid scars mostly affected persons
between 10 and 30 years of age, in  Blacks and
Asians race, with predisposition in individuals with
human leukocyte antigen (HLA) B 14, BW 16 and
blood group A.5
The pathology of keloids remains poorly
understood.  In vitro researches had shown that
keloid scars were considered to be a result of
abnormal wound healing, due to overproliferation
of fibroblast followed by low activities of
collagenase that caused overexcessive collagen in
the wound.3 Fibroblast proliferation was stimulated
by growth factors and cytokines, such as vascular
endothelial growth factor (VEGF),6 transforming
growth factor beta (TGF-b), tumor necrosis factor
alfa (TNF-α), and interleukin 6 (IL-6).7 The most
important factor is TGF-b8,  followed by VEGF.6
Keloid scars exclusively affected Homo-
sapiens, and that is why no experiments were
possible in animal models. The experiment for
keloids usually used in vitro model that investigated
the organization of collagen fibers by fibroblast in
fibroblast populated collagen lattice (FPCL)
contraction model. It was composed of cultured
fibroblast suspended in collagen lattice isolated from
rat tail. This model was a dermal equivalent, which
was usually used for fibroblast activities
measurement.9,10
Keloid therapy was fraught with varying
degrees of success. There was no one modality
that was always successful. Various methods had
been developed to treat keloid, from pharmacologic
treatments such as triamcinolone acetonide (TA),11
tretinoin,12 tacrolimus,13 5-flourourasil (5-FU),14
tamoxifen,15 to surgery.1 All of these modalities had
unsatisfactory results, the keloid flattening was
followed by high rates of recurrences.1,3 The most
commonly used therapeutics for keloid was
intralesion TA injection as a single modality or
combined with others.1,5 A study showed that 10
mM TA caused a significant decrease in the
production of TGF-b keloid fibroblast2 with side
effect like severe pain, atrophy, hypopigmentation
or Cushing’s syndrome after several injection.16
Methotrexate (MTX) is a chemotherapeutic
agent having an anti-proliferating effect which act
as a folic acid antagonist that usually used to treat
breast cancer,17 acute lymphoblastic leukaemia,18
psoriasis,19 rheumatoid arthritis,20 and kerato-
achantoma tumor as a intralesional treatment with
no local or systemic adverse effects from the
therapy.21,22
As an immunosuppressant, MTX might cause
suppression of TNF-α, IL-6,23 TGF-b,24 and also
had anti-angiogenesis effect,17 that decreases the
level of VEGF.25 Muzaffar26  and Tonkin27 reported
success in treating keloid with oral low dose MTX
combined with surgery and no recurrences.
However, the combination of MTX with TA in keloid
derived fibroblast proliferation as well as in collagen
synthesis had not been published.
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FIGURE.1. Average contraction percentage of FPCL with
treatment (TA) and control
METHODS
Keloid dermal fibroblast primary cultures
Primary cell lines of keloid dermal fibroblasts
were established from operating room specimens.
The keloid tissue was taken from deltoid region. A
standard explant method was used to establish the
primary fibroblast cultures from the operative
specimens. This explant method was performed
using sterile technique under a laminary flow hood.
After all of the subcutaneous tissue was removed
with a sterile scalpel blade, the gross specimens
were minced into small fragments in a petri dish.
The specimens underwent antimicrobial treatment
with Dulbecco’s phosphate-buffered saline (PBS)
solution with 5% penicillin/streptomycin/
amphotericin (PSA). Minced fragments measuring
approximately 1 mm were then placed into tissue
culture flasks containing 5 ml of explant tissue
culture media (40% fetal calf serum in Dulbecco’s
modified eagle medium with 1% PSA). These flasks
were then stored in a humidified incubator
containing a 5% CO2  atmosphere at 37°C. The
explant-containing flasks were examined daily under
light microscopy for the outgrowth of fibroblasts
from the tissue fragments. Until light microscopy
demonstrated such fibroblast outgrowth, explant
tissue culture media was changed daily. Once
fibroblast outgrowth approached confluence, the
tissue fragments were removed. The fibroblasts
were then trypsinized with 0.05% trypsin and
subcultured into culture flasks containing 10 ml of
primary culture media (10% fetal calf serum in
Dulbecco’s modified eagle medium with 1% PSA).
All flasks were stored in a humidified incubator
containing a 5% CO2 atmosphere at 37 °C. Primary
culture media was changed twice a week.
Successive cultures were passed at confluence.
Experiments were performed using passage 3
keloid fibroblasts.
Preparation of fibroblast-populated collagen
lattices
Collagen lattices were prepared from type 1
collagen extracted from rat tail tendons in 0.1%
(vD v) acetic acid. A working solution was
constituted by diluting the collagen to 2 mg/ml on
the day of the experiment. Keloid fibroblast was
trypsinized, resuspended in medium and counted
using a haemocytometer. A collagen–keloid
fibroblast suspension was prepared in DMEM and
divided into 16 groups, then treated with 5, 10, 20
µM TA, 1,75, 3.5, 7 µM MTX, combination of TA
and MTX, and a control negative. Fibroblast-
populated collagen lattices with treatments were
seeded into the wells of 24-well plates at density of
6 × 104 cells/ml. Plates were kept in an incubator
with 5% CO2 at 37°C.
Macroscopic evaluation of the gel
contraction
The area of collagen gel populated with
fibroblasts was photographed with a digital camera
(Olympus SLR E.500) at day 0, 1, 2 and 3 after the
experiment had begun, the gel area was calculated
with Scion Image software. The percentage of gel
contraction in each interval studied was calculated
with the following formula:
Percentage of contraction = 100
)(
1
21


A
AA
where: A1 is initial gel area and A2 is the area at the
observed intervals.
Statistical Analysis
The gel contraction data were analyzed using
ANOVA and were expressed as mean percentage
of contraction and standard deviation. Posthoc test
used Tukey HSD with p<0.05.
RESULTS
The mean inhibition of FPCL contraction
between treatment and control groups were shown
as a graphic (FIGURE 1-3).
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FIGURE 2. Average contraction percentage of FPCL with
treatment (MTX) and control
FIGURE 3. The best average contraction percentage of
FPCL with treatment (MTX, TA, combination of MTX
and TA) and control.
FIGURE 1 and 2 show that all treatments with
various doses of TA and MTX given separately
caused a statistically significant (p<0.05) inhibition
on FPCL contraction until day 2, compared to
control. The inhibition of FPCL contraction was in
dose-dependent manner, a higher dose of TA or
MTX may paradoxically increase inhibition of FPCL
contraction.
From the combination of TA and MTX groups
(data were not shown), we found a similar result
with treatment group which given separately. All
various doses combination of TA and MTX caused
a statistically significant (p<0.05) inhibition on FPCL
contraction until day 2, compared to control. A
higher dose of combination treatment might increase
the inhibition of FPCL contraction. The best inhibition
of FPCL contraction from each combination of TA
and MTX was found in all various doses of MTX
with 20 µM TA.
FIGURE 3 shows that all treatments could
inhibit FPCL contraction until day 2 (p<0.05). The
highest inhibition of FPCL was found in combination
of TA 20 µM + MTX 7 µM (p<0.05). The treatment
that could inhibit FPCL contraction until day 3 was
only group MTX 3.5 µM + TA 20 µM combination
(post-hoc test). This result indicated that a
combination of TA and MTX would be stronger in
inhibiting keloid fibroblast activities than TA and
MTX given separately.
DISCUSSION
Experiments with cells derived from keloid
tissue revealed a number of abnormalities in cellular
functions, such as in proliferation, apoptosis, or
expression of growth factors.3 The most important
factor is TGF-α,9,10,28 followed by VEGF,6,29,30
IL6,7,30 and TNF-α.31
Keloid explants embedded in collagen lattice
were morphologically similar with in vivo wound
healing,  it could be used for maintaining long-term
viable keloid dermal explants until 6 weeks as a
tool for investigating the pathogenesis of keloid scar
formation.32 FPCL were used for investigating TGF-
ß,9,10 FGF,10 5-FU,14 chitin, and chitosan on keloid.33
This study (FIGURE1-3) showed the
differences of average contraction percentage of
FPCL with treatment and control on day 1 until 3.
This result indicated a viable fibroblast keloid and
the consistency of FPCL contraction due to the
treatment.
Triamcinolone acetonide (TA) could alter matrix
extracellular due to fibroblast proliferation and TGF-
ß. Cruz and Korchin found that 10 µM TA caused
statistically significant growth inhibition of keloid
and fetus fibroblasts.34 Carrol2 found that 10 and
20 µM TA caused a statistically significant decrease
in the level of TGF-ß keloid fibroblast on day 1.
Exposure with 5 µM TA did not cause a statistically
significant decrease in the level of TGF-ß. A higher
dose of TA may increase cellular proliferation.2
The result from our study (FIGURE 1) showed
that not only 10 and 20 µM TA, but also 5 µM TA
caused a statistically significant (p<0.05) inhibition
of FPCL contraction until day 2, compared to
control. The different results may be caused by
different methods, previous study were not used
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FPCL and inhibition of FPCL were not only caused
by TGF- ß. The inhibition of FPCL contraction was
in dose-dependent manner, a higher dose of TA or
MTX might paradoxically increase inhibition of
FPCL contraction.
Methotrexate (MTX) had been shown to
suppress TNF-α due to apoptosis.35  Neurath23
found that 1-10 µg/ml MTX on murine caused
suppression TNF-a and IL-6. Sigmundsdottir36
found that 1-10 µM MTX markedly reduced the
expression of vascular E-selectin and ICAM 1 in
psoriatic skin, and no further inhibition was observed
after 10 µM MTX. This result was similar with our
study. FIGURE 2 shows that 1.75, 3.5 and 7 µM
MTX caused a statistically significant (p<0.05)
inhibiton on FPCL contraction until day 2, compared
with control it was due to the inhibition of fibroblast
proliferation, TNF-α, or may be the other factors,
on dose-dependent.
The study of combination MTX with other
chemotherapy or immunosuppresant for cancer or
rheumatoid arthritis had been conducted. The target
mechanism was VEGF, TGF ß1 and TNF-a. Low-
dose MTX with cyclophosphamide caused
significant decreased level of VEGF in breast
cancer,17 and with dexamethasone in rheumatoid
artrithis.37 Combination of 5-FU and cyclophospha-
mide caused significant decreased plasma TGF-
ß1 concentration in breast cancer.24 Muzaffar26 and
Tonkin27 reported a success in treating keloid with
oral low dose MTX combined with reconstruction
syndactily with no recurrences. In our study, all
treatments with various doses of MTX and TA
given separately or in combination could inhibit
FPCL contraction until day 2 (p<0.05), except in
group MTX 3.5  µM + TA 20 mM combination that
could inhibit FPCL contraction until day 3 (p<0.05)
(post-hoc test). That combination might be an ideal
dose to get synergism effect. The highest inhibition
of FPCL was found in combination of TA 20 µM +
MTX 7 µM (p<0.05). This result indicated that
combination of TA and MTX would inhibit further
the keloid fibroblast activities than TA or MTX given
separately. This result might be based on synergistic
or additive effects of the drugs.
To summarize, we had demonstrated that the
inhibition of FPCL contraction was dose-dependent,
a higher dose of TA or MTX might paradoxically
increase the inhibition of FPCL contraction. The
combination of TA and MTX would inhibit further
keloid fibroblast activities than TA or MTX given
separately; strongly suggesting based on synergistic
or additive effects of the drugs. These data
suggested a new therapeutic approach for keloid.
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